|
CA2744997A1
(en)
*
|
2003-09-26 |
2005-04-07 |
Exelixis, Inc. |
C-met modulators and method of use
|
|
EP1719762B1
(en)
|
2004-02-27 |
2012-06-27 |
Eisai R&D Management Co., Ltd. |
Novel pyridine derivative and pyrimidine derivative (1)
|
|
CA2573538C
(en)
*
|
2004-07-30 |
2014-11-25 |
Methylgene Inc. |
Inhibitors of vegf receptor and hgf receptor signaling
|
|
ES2473341T3
(es)
|
2005-05-20 |
2014-07-04 |
Methylgene Inc |
Inhibidores de la se�alizaci�n del receptor del VEGF y del receptor del HGF
|
|
JP5148499B2
(ja)
*
|
2005-05-20 |
2013-02-20 |
メチルジーン インコーポレイテッド |
Ｖｅｇｆ受容体およびｈｇｆ受容体シグナル伝達の阻害剤
|
|
KR20080026562A
(ko)
*
|
2005-06-02 |
2008-03-25 |
갤럭시 바이오테크, 엘엘씨 |
항체를 이용한 뇌종양 치료 방법
|
|
PL1889836T3
(pl)
|
2005-08-24 |
2013-10-31 |
Eisai R&D Man Co Ltd |
Nowa pochodna pirydyny i pochodna pirymidyny (3)
|
|
AU2006309171A1
(en)
*
|
2005-10-28 |
2007-05-10 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
|
NL2000291C2
(nl)
|
2005-11-10 |
2009-02-17 |
Pfizer Prod Inc |
1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
|
|
AR059246A1
(es)
|
2006-01-30 |
2008-03-19 |
Array Biopharma Inc |
Compuestos heterobiciclicos de tiofeno y metodos de uso
|
|
MX2008011220A
(es)
|
2006-03-07 |
2008-09-11 |
Array Biopharma Inc |
Compuestos de pirazol heterobiciclicos y metodos de uso.
|
|
AR059922A1
(es)
*
|
2006-04-01 |
2008-05-07 |
Galaxy Biotech Llc |
Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
|
|
JP5302883B2
(ja)
|
2006-04-07 |
2013-10-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
医薬組成物用のｍｎｋ１／ｍｎｋ２阻害活性を有するチエノピリミジン
|
|
US20110053931A1
(en)
*
|
2006-06-08 |
2011-03-03 |
John Gaudino |
Quinoline compounds and methods of use
|
|
EP1889847A1
(en)
|
2006-07-10 |
2008-02-20 |
DeveloGen Aktiengesellschaft |
Pyrrolopyrimidines for pharmaceutical compositions
|
|
JP2010500365A
(ja)
|
2006-08-07 |
2010-01-07 |
インサイト・コーポレイション |
キナーゼ阻害剤としてのトリアゾロトリアジン
|
|
CN101454311B
(zh)
|
2006-08-23 |
2013-03-27 |
卫材R&D管理有限公司 |
苯氧基吡啶衍生物的盐和其结晶及其制备方法
|
|
US7790885B2
(en)
|
2006-08-31 |
2010-09-07 |
Eisai R&D Management Co., Ltd. |
Process for preparing phenoxypyridine derivatives
|
|
WO2008049855A2
(en)
*
|
2006-10-27 |
2008-05-02 |
Glaxo Group Limited |
7-azaindole derivatives as c-met kinase inhibitors
|
|
ES2560435T3
(es)
|
2006-11-22 |
2016-02-19 |
Incyte Holdings Corporation |
Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa
|
|
BRPI0722383A2
(pt)
|
2006-12-08 |
2012-06-05 |
Irm Llc |
compostos inibidores de proteìna quinase, composições contendo os mesmos bem como seus usos
|
|
DE102007026341A1
(de)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
|
CN101918403A
(zh)
*
|
2007-09-06 |
2010-12-15 |
阵列生物制药公司 |
作为酪氨酸激酶抑制剂的吡唑并吡啶类化合物
|
|
JP2009132660A
(ja)
|
2007-11-30 |
2009-06-18 |
Eisai R & D Management Co Ltd |
食道癌治療用組成物
|
|
WO2009109035A1
(en)
|
2008-03-05 |
2009-09-11 |
Methylgene Inc. |
Inhibitors of protein tyrosine kinase activity
|
|
MX393622B
(es)
|
2008-05-21 |
2025-03-24 |
Incyte Corp |
Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas.
|
|
HRP20140395T1
(hr)
*
|
2008-08-20 |
2014-06-06 |
Zoetis Llc |
SPOJEVI PIROLO[2,3-d]PIRIMIDINA
|
|
KR20110045019A
(ko)
|
2008-08-26 |
2011-05-03 |
베링거 인겔하임 인터내셔날 게엠베하 |
약제학적 조성물을 위한 티에노피리미딘
|
|
CA2740746A1
(en)
*
|
2008-10-14 |
2010-04-22 |
Ning Xi |
Compounds comprising a spiro-ring and and methods of use
|
|
DE102009003975A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Benzothiazolonderivate
|
|
EA038195B1
(ru)
|
2009-01-16 |
2021-07-22 |
Экселиксис, Инк. |
Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее применение для лечения рака почек и печени
|
|
EP2408300B1
(en)
*
|
2009-03-21 |
2016-05-11 |
Sunshine Lake Pharma Co., Ltd. |
Amino ester derivatives, salts thereof and methods of use
|
|
EP2245936A1
(en)
|
2009-04-27 |
2010-11-03 |
Bayer CropScience AG |
Use of 4-aza indole derivatives for the reduction of mycotoxin contamination
|
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
IN2012DN02577A
(enExample)
*
|
2009-10-15 |
2015-08-28 |
Pfizer |
|
|
DE102009056886A1
(de)
|
2009-12-03 |
2011-06-09 |
Bayer Schering Pharma Aktiengesellschaft |
cMet-Inhibitoren zur Behandlung der Endometriose
|
|
JP5714030B2
(ja)
|
2010-02-03 |
2015-05-07 |
インサイト コーポレーションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ |
Ｃ−Ｍｅｔ阻害剤としてのイミダゾ［１，２−ｂ］［１，２，４］トリアジン
|
|
AR080328A1
(es)
|
2010-02-26 |
2012-03-28 |
Boehringer Ingelheim Int |
Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros
|
|
UY33241A
(es)
|
2010-02-26 |
2011-09-30 |
Boehringer Ingelheim Int |
?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
|
|
EA201201191A1
(ru)
|
2010-02-26 |
2013-04-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
4-[циклоалкилокси(гетеро)ариламино]тиено[2,3-d]пиримидины, обладающие ингибирующей активностью по отношению к mnkl/mnk2, предназначенные для фармацевтических композиций
|
|
EP3450432A1
(en)
|
2010-05-17 |
2019-03-06 |
Incozen Therapeutics Pvt. Ltd. |
Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued - 3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
|
|
WO2011146287A1
(en)
|
2010-05-20 |
2011-11-24 |
Takeda Pharmaceutical Company Limited |
Pyrazolo[4,3-b]pyridine-7-amine inhibitors of alk5
|
|
CA2802644C
(en)
|
2010-06-25 |
2017-02-21 |
Eisai R & D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
|
WO2012009722A1
(en)
|
2010-07-16 |
2012-01-19 |
Exelixis, Inc. |
C-met modulator pharmaceutical compositions
|
|
DK2621481T4
(da)
|
2010-09-27 |
2023-01-09 |
Exelixis Inc |
Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser
|
|
US9309322B2
(en)
|
2010-11-12 |
2016-04-12 |
Scott & White Healthcare (Swh) |
Antibodies to tumor endothelial marker 8
|
|
TWI640509B
(zh)
|
2011-02-10 |
2018-11-11 |
艾克塞里克斯公司 |
製造喹啉化合物之方法及包含該化合物之醫藥組合物
|
|
US20120252840A1
(en)
|
2011-04-04 |
2012-10-04 |
Exelixis, Inc. |
Method of Treating Cancer
|
|
TWI610918B
(zh)
|
2011-05-02 |
2018-01-11 |
艾克塞里克斯公司 |
治療癌症及骨癌疼痛之方法
|
|
TW201311679A
(zh)
|
2011-08-04 |
2013-03-16 |
Takeda Pharmaceutical |
含氮雜環化合物
|
|
ES2575710T3
(es)
|
2011-09-22 |
2016-06-30 |
Pfizer Inc |
Derivados de pirrolopirimidina y purina
|
|
GEP201606523B
(en)
|
2011-09-22 |
2016-08-10 |
Exelixis Inc |
Method for treating osteoporosis
|
|
EP2768796B1
(en)
*
|
2011-10-20 |
2019-11-20 |
Exelixis, Inc. |
Process for preparing quinoline derivatives
|
|
US9586965B2
(en)
|
2012-01-13 |
2017-03-07 |
Acea Biosciences Inc. |
Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
|
|
AU2013207712B2
(en)
|
2012-01-13 |
2017-08-31 |
Acea Biosciences Inc. |
Heterocyclic compounds and uses as anticancer agents.
|
|
US9464089B2
(en)
|
2012-01-13 |
2016-10-11 |
Acea Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
US9034885B2
(en)
|
2012-01-13 |
2015-05-19 |
Acea Biosciences Inc. |
EGFR modulators and uses thereof
|
|
AP3908A
(en)
|
2012-03-30 |
2016-11-24 |
Rhizen Pharmaceuticals Sa |
Novel 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo [4,5-B] pyridine compounds as modulators of C-met protein kinases
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
WO2013166296A1
(en)
|
2012-05-02 |
2013-11-07 |
Exelixis, Inc. |
A dual met - vegf modulator for treating osteolytic bone metastases
|
|
TWI520962B
(zh)
|
2012-06-29 |
2016-02-11 |
|
As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives
|
|
CN104507930B
(zh)
*
|
2012-06-29 |
2017-10-10 |
贝达药业股份有限公司 |
作为c‑Met酪氨酸激酶抑制剂的新型稠合吡啶衍生物
|
|
CN103570723B
(zh)
*
|
2012-07-27 |
2016-07-13 |
广西梧州制药（集团）股份有限公司 |
吡唑并嘧啶衍生物及其制备方法和在药物制备中的用途
|
|
EP2917216B1
(en)
|
2012-11-08 |
2017-10-18 |
Pfizer Inc |
Heteroaromatic compounds as dopamine d1 ligands
|
|
CN102964308B
(zh)
*
|
2012-11-30 |
2015-03-18 |
中国药科大学 |
新型嘧啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
|
|
AU2013364953A1
(en)
|
2012-12-21 |
2015-04-30 |
Eisai R&D Management Co., Ltd. |
Amorphous form of quinoline derivative, and method for producing same
|
|
CA2907334C
(en)
|
2013-03-15 |
2021-12-07 |
Exelixis, Inc. |
Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
|
|
US11564915B2
(en)
|
2013-04-04 |
2023-01-31 |
Exelixis, Inc. |
Cabozantinib dosage form and use in the treatment of cancer
|
|
KR20150138268A
(ko)
*
|
2013-04-04 |
2015-12-09 |
엑셀리시스, 인코포레이티드 |
암을 치료하기 위한 약물 병용요법
|
|
CN105264380B
(zh)
|
2013-05-14 |
2017-09-05 |
卫材R&D管理有限公司 |
用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
|
|
KR102173433B1
(ko)
|
2013-07-11 |
2020-11-04 |
에이시아 바이오사이언시스 인코포레이티드. |
키나아제 억제제로써의 피리미딘 유도체
|
|
AU2015218236B2
(en)
|
2014-02-14 |
2019-06-13 |
Exelixis, Inc. |
Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
|
|
MX2016012285A
(es)
|
2014-03-24 |
2017-01-23 |
Genentech Inc |
Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
|
|
WO2015162515A1
(en)
|
2014-04-25 |
2015-10-29 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
|
WO2015162518A1
(en)
|
2014-04-25 |
2015-10-29 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
|
CN106715397B
(zh)
|
2014-07-31 |
2021-07-23 |
埃克塞里艾克西斯公司 |
制备氟-18标记的卡博替尼及其类似物的方法
|
|
BR112017002318A2
(pt)
|
2014-08-05 |
2018-07-17 |
Exelixis, Inc. |
combinações de fármacos para tratar mieloma múltiplo.
|
|
CA2957005C
(en)
|
2014-08-28 |
2021-10-12 |
Eisai R&D Management Co., Ltd. |
High-purity quinoline derivative and method for manufacturing same
|
|
SG11201706630UA
(en)
|
2015-02-25 |
2017-09-28 |
Eisai R&D Man Co Ltd |
Method for suppressing bitterness of quinoline derivative
|
|
WO2016140717A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
|
BR112017027227B1
(pt)
|
2015-06-16 |
2023-12-12 |
Eisai R&D Management Co., Ltd |
Agente anti-câncer
|
|
JP6721617B2
(ja)
*
|
2015-07-20 |
2020-07-15 |
ベータ ファーマシューティカルズ カンパニー リミテッド |
縮合ピリジン誘導体のマレエートの結晶形態およびその使用
|
|
EP3325473A4
(en)
|
2015-07-22 |
2019-06-26 |
The Royal Institution for the Advancement of Learning / McGill University |
Compounds and uses thereof in the treatment of cancer and other medical disorders
|
|
JP6553726B2
(ja)
|
2015-08-20 |
2019-07-31 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療剤
|
|
WO2017059702A1
(en)
|
2015-10-09 |
2017-04-13 |
Acea Biosciences, Inc |
Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
|
|
GB201520500D0
(en)
|
2015-11-20 |
2016-01-06 |
Medical Res Council Technology |
Compounds
|
|
GB201520499D0
(en)
|
2015-11-20 |
2016-01-06 |
Medical Res Council Technology |
Compounds
|
|
CN109069499A
(zh)
|
2016-04-15 |
2018-12-21 |
埃克塞里艾克西斯公司 |
使用 n-(4-(6,7-二甲氧基喹啉-4-基氧基)苯基)-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺,(2s)-羟基丁二酸盐治疗肾细胞癌的方法
|
|
CN106496232B
(zh)
*
|
2016-09-22 |
2018-11-09 |
南方医科大学 |
一种具有抗肿瘤活性的1-(2-四氢吡喃)-1H-吡唑并[3,4-d]嘧啶类化合物及其制备方法
|
|
US12303505B2
(en)
|
2017-02-08 |
2025-05-20 |
Eisai R&D Management Co., Ltd. |
Tumor-treating pharmaceutical composition
|
|
US11498922B2
(en)
|
2017-04-07 |
2022-11-15 |
ACEA Therapeutics, Inc. |
Pharmaceutical composition comprising N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenylacrylamide
|
|
BR112019023064A2
(pt)
|
2017-05-16 |
2020-06-09 |
Eisai R&D Man Co Ltd |
tratamento de carcinoma hepatocelular
|
|
WO2018228923A1
(en)
|
2017-06-13 |
2018-12-20 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases
|
|
WO2018228925A1
(en)
|
2017-06-13 |
2018-12-20 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
CA3066859A1
(en)
|
2017-06-13 |
2018-12-20 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
US11427578B1
(en)
|
2017-07-18 |
2022-08-30 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
AU2019216351B2
(en)
|
2018-01-31 |
2024-07-25 |
Deciphera Pharmaceuticals, Llc |
Combination therapy for the treatment of mastocytosis
|
|
EP3746059B1
(en)
|
2018-01-31 |
2026-03-04 |
Deciphera Pharmaceuticals, LLC |
Combination therapy for the treatment of gastrointestinal stromal tumors
|
|
CN120305263A
(zh)
|
2018-06-15 |
2025-07-15 |
汉达癌症医药责任有限公司 |
卡博替尼的盐类于制备治疗癌症的剂型的用途
|
|
UY38349A
(es)
|
2018-08-30 |
2020-03-31 |
Array Biopharma Inc |
Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
|
|
US20220047603A1
(en)
|
2018-12-11 |
2022-02-17 |
Bayer Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
ES2974634T3
(es)
|
2018-12-21 |
2024-06-28 |
Celgene Corp |
Inhibidores de tienopiridinas de RIPK2
|
|
NL2022471B1
(en)
|
2019-01-29 |
2020-08-18 |
Vationpharma B V |
Solid state forms of oclacitinib
|
|
WO2020185812A1
(en)
|
2019-03-11 |
2020-09-17 |
Teva Pharmaceuticals International Gmbh |
Solid state forms of ripretinib
|
|
KR20220054286A
(ko)
*
|
2019-06-25 |
2022-05-02 |
시놉세 테라페우틱스 |
눈 장애의 치료를 위한 화합물
|
|
FI4013412T3
(fi)
|
2019-08-12 |
2026-03-24 |
Deciphera Pharmaceuticals Llc |
Ripretinibi ruoansulatuskanavan stroomakasvaimien hoitoon
|
|
TWI878335B
(zh)
|
2019-08-12 |
2025-04-01 |
美商迪賽孚爾製藥有限公司 |
治療胃腸道基質瘤方法
|
|
PL4084779T3
(pl)
|
2019-12-30 |
2025-02-24 |
Deciphera Pharmaceuticals, Llc |
Kompozycje 1-(4-bromo-5-(1-etylo-7-(metyloamino)-2-okso-1,2-dihydro-1,6-naftyrydyn-3-ylo)-2-fluorofenylo)-3-fenylomocznika
|
|
AU2020419197B2
(en)
|
2019-12-30 |
2023-08-31 |
Deciphera Pharmaceuticals, Llc |
Amorphous kinase inhibitor formulations and methods of use thereof
|
|
WO2021249913A1
(en)
|
2020-06-09 |
2021-12-16 |
Bayer Aktiengesellschaft |
2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
|
|
US20240174683A1
(en)
|
2021-02-05 |
2024-05-30 |
Bayer Aktiengesellschaft |
Map4k1 inhibitors
|
|
CN116836176B
(zh)
*
|
2022-03-23 |
2026-02-24 |
中国科学院上海药物研究所 |
青蒿素类化合物、其制备方法和应用
|
|
CN115160340B
(zh)
*
|
2022-06-07 |
2023-07-21 |
四川大学华西医院 |
一种具有ack1抑制活性的小分子化合物及其应用
|
|
US11779572B1
(en)
|
2022-09-02 |
2023-10-10 |
Deciphera Pharmaceuticals, Llc |
Methods of treating gastrointestinal stromal tumors
|
|
EP4622961A1
(en)
*
|
2022-11-25 |
2025-10-01 |
Synthon B.V. |
A process for preparation of cabozantinib or tivozanib
|
|
AU2024215796A1
(en)
|
2023-01-31 |
2025-05-15 |
Handa Oncology, Llc |
Improved cabozantinib compositions and methods of use
|